Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the United States and is projected to maintain a substantial market lead over ritlecitinib.
This article was originally published by Dermatology Times®. This version is lightly edited.
Man with bald patches
Image credit: alex papp - adobe.stock.com
Bariticinib (Olumiant; Eli Lilly) is prescribed by a majority of US dermatologists to their patients with alopecia areata (AA), according to a recent analysis. Additionally, more than half of US dermatologists have begun trials of ritlecitinib (Litfulo; Pfizer) in their patients with AA.
According to the analysis, 6-month market projections for both drugs are favorable. However, bariticinib is expected to maintain a substantial market lead over ritlecitinib.
Spherix Global Insights notes that within the past 4 years of their analysis of the AA market, the introduction of Janus kinase (JAK) inhibitors has made a significant impact on the market itself, particularly attributable to its ability to meet an unmet need in severe alopecia.
The analysis found that 105 US dermatologists currently prescribe baricitinib to their patients with AA, potentially attributable to the JAK inhibitor's earlier introduction in the space for AA management.
A specific analysis of 520 charts of patients who have AA reaffirmed this prescription rate, with prescribers noting the choice to prescribe baricitinib could mostly be attributable to familiarity and comfort. The most common factor for initiating treatment with ritlecitinib, the analysis found, was a prescriber and patient desire to trial a newer therapy.
Despite the difference in the number of dermatologists prescribing bariticinib vs ritlecitinib for patients with AA, the analysis found that prescribers of both drugs expressed comparable and high levels of satisfaction. In fact, these rates of satisfaction were significantly greater than rates for nonadvanced systemic treatments.
Both drugs received equally favorable evaluations of overall patient satisfaction, eyebrow and eyelash regrowth, and Severity of Alopecia Tool scoring.
"Recent data from Spherix's published studies highlight minimal differentiation among prescribers regarding the 2 JAK inhibitors," according to Spherix. "A significant portion—two-fifths—explicitly state no differentiation between the two, while one-quarter of the remaining respondents emphasize that dosing represents the most notable contrast. Fewer than one-fifth report differences in access and efficacy between the brands."
The analysis also found that for manufacturers of both drugs, "Dermatologists expressed a shared need for support in access/improvement of patient assistance programs, increased provision of samples, enhanced resources for patient and physician education, and an overall demand for more comprehensive data."
Despite these expressed needs, Spherix found that prescribers were generally unaware of the AA drug pipeline. Most prescribers involved in the analysis were not able to recall other AA treatments aside from JAK inhibitors in development, but were able to recall well-known line-extensions such as upadacitinib (Rinvoq; AbbVie) and deucravacitinib (Sotyktu; BMS) when prompted.
The top drugs currently in development, ranked by prescribers based on familiarity, included deuruxolitinib (Sun Pharmaceutical Industries), etrasimod (Velsipity; Pfizer), bempikibart (Q32 Bio andAmgen/Horizon), and ivarmacitinib (Arcutis).
Less familiar to prescribers were 3 novel therapies currently in development: daxdilimab (Amgen/Horizon), farudostat (ASLAN Pharmaceuticals), and EQ101 (Equillium).
Reference
Eli Lilly’s Olumiant and Pfizer’s Litfulo strengthen alopecia areata arsenal, yet resounding opportunity for JAK expansion and new assets in development remain. GlobeNewswire. Spherix Global Insights. November 15, 2023. Accessed November 16, 2023. https://www.globenewswire.com/news-release/2023/11/15/2781240/0/en/Eli-Lilly-s-Olumiant-and-Pfizer-s-Litfulo-Strengthen-Alopecia-Areata-Arsenal-Yet-Resounding-Opportunity-for-JAK-Expansion-and-New-Assets-in-Development-Remain.html
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More